Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
The program addresses all three major barriers to bending the obesity curve in the US: excessive US prices of medication, medication side effects, and sustainable lifestyle change
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) — Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate. The Microdose GLP-1Rx Program is priced at $119 to start, followed by $199 per month, which includes medication, if prescribed, and Noom's powerful GLP-1 Companion, providing clinical care, coaching, and a personalized healthy habits program.
The US obesity rate, after decades of unstoppable growth, has at last started to plateau, but at a level that continues to lead the developed world. The US rate of obesity stands at more than 40% versus the UK at 26%, Germany at 23%, and France at 10%. Meanwhile, GLP-1 medications cost as much as 5x more in the US than in these same countries. Three core barriers prevent broader and faster progress: medication cost, medication side effects, and the lack of sustainable behavior change. Noom's Microdose GLP-1Rx Program directly addresses each of these three barriers, to help meaningfully bend the obesity curve.
Only affordable GLP-1s and Behavior Change will bend this curve.
Noom's physician-designed program employs a 'low and slow' titration approach with microdoses that are a fraction of conventional maintenance doses. Noom's data has shown that members on microdoses are far less likely to have destabilizing side effects. In fact, 70% of Noom members receiving microdoses report no side effects at all. At the same time, members achieve up to 11 pounds of weight loss in 30 days and up to 17 pounds in 60 days at microdose dosages. Meanwhile, studies indicate the vast majority–more than 70%–of patients on standardized protocols experience side effects .
'In the Microdose GLP-1Rx Program, we set out to virtually eliminate side effects for the vast majority, so that more than 70% of people would encounter no side effects. In both my clinical experience and evidence in published studies, it is clear that many people discontinue GLP-1 treatment because of side effects,' said Dr. Jeffrey Egler, Chief Medical Officer at Noom. 'The Noom Microdose GLP-1Rx Program was designed to address this issue by introducing GLP-1s gradually and sustaining them at a microdose level, as part of a larger holistic behavior change platform, which we call our GLP-1 Companion. This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States.'
Noom's Microdose GLP-1Rx Program is based on scientific principles: Self-efficacy boosts success with healthy habits . GLP-1 medication makes it easier to adopt healthy habits, while healthy habits improve health outcomes. Members who engage with Noom's GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged. Noom members on GLP-1s actually log more meals, weigh in more often, and log more exercise by their second month than those on Noom without a GLP-1.
. GLP-1 medication makes it easier to adopt healthy habits, while healthy habits improve health outcomes. Members who engage with Noom's GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged. Noom members on GLP-1s actually log more meals, weigh in more often, and log more exercise by their second month than those on Noom without a GLP-1. Strong weight loss outcomes at lower doses are both achievable and well established in the literature. A 2,700‑person real‑world study presented at the 2025 European Congress on Obesity showed an average 16% weight‑loss over 64 weeks at microdose levels of semaglutide. Meanwhile, another study in The New England Journal of Medicine shows just 33% of the dose of one popular GLP-1 drove 72% of the weight loss at week 72 with a lower side effect profile.
A 2,700‑person real‑world study presented at the 2025 European Congress on Obesity showed an average of semaglutide. Meanwhile, another study in shows just with a lower side effect profile. The benefits from GLP-1s extend beyond weight . Recent analyses presented at the National Lipid Association's 2025 Scientific Sessions highlighted cardiovascular, renal, and metabolic gains from GLP‑1s that appear partly independent of the amount of weight loss. Other studies show a similar impact on inflammatory markers independent of weight loss.. Meanwhile, other studies demonstrate a reduction in compulsive behaviors like drinking and gambling .
Taken together, the evidence is clear: microdoses of GLP-1 paired with microhabits can unlock outsized health benefits.
What is a Microdose?
Noom defines a microdose as a dose of medication that is a fraction – 25% or less – of the typically prescribed maintenance dose. Noom's microdose dosing schedule is not one-size-fits-all. It accesses doses lower than the usual starter doses as well as additional doses up to 25% of the standard maintenance dose.
Within that band, the exact dosage schedule is established one member at a time: our physician-prescribed protocol, aided by Noom's SmartDose experience, guides members to the lowest dose that achieves health goals. Factors influencing that decision include BMI, weight loss speed, side effect profile, and other health data.
'Noom has a unique, proprietary dataset that permits the level of deep personalization that our program deploys,' continued Dr. Jeffrey Egler. 'The Noom program has comprehensive data on patient health, injection dates, side effects, and weight-loss speed, and we bring that data to bear to personalize the dosing to maximize outcomes and adherence not just to the medication, but to our Noom microhabits program.'
While many eligible GLP-1 users are deterred from starting medication due to fear of incurring side effects, others are challenged by high medication costs. Among those who do start using GLP-1s, over 50% stop due to costs , and as many as 36% stop due to side effects .
Noom's Microdose GLP-1Rx Program bridges this gap by offering a more personalized, tolerable path to treatment. It is built on a guiding principle of using the lowest effective dose first. Rather than increasing medication on a fixed schedule, Noom's physician-designed protocol adjusts dosing based on each patient's individual progress and response. This approach enables personalized care that supports meaningful weight loss while minimizing side effects and helping more people adhere to the treatment.
GLP-1s and Weight Loss Accessibility – Solving Today's High-Priced Drug Crisis
GLP-1 medications continue to be significantly more affordable around the world than in the United States. Popular GLP-1 medications are priced around $99 a month in many developed nations, but at $499 a month to cash-pay patients in the United States. Cost is a major barrier to accessibility in the US, where the price of medications and healthcare services are often much higher than internationally.
Noom's accessibly priced Microdose GLP-1Rx Program, starting at $119, builds on the company's advocacy efforts on behalf of patients in the US. In April 2025, Noom sponsored a back cover advertisement in the The Wall Street Journal calling for the creation of a High-Priced Drug List by HHS. The High-Priced Drug List is a market-based solution enabling competition from the country's 503A and 503B pharmacies when medications are priced higher in the United States compared to other developed countries.
In addition to the launch of Noom's Microdose GLP-1Rx Program, on Wednesday, July 30th, at an event at The White House, Noom pledged to make available a free tier of Noom to all Americans – regardless of income or BMI. The free tier will launch before the end of the summer and deliver a personalized experience focused on building healthy habits in nutrition, physical activity, and stress reduction. 'Medication alone will not end the obesity epidemic. Lifestyle change is essential,' said Cook. 'By offering a no-cost way for anyone to build healthy habits with Noom, we can reach millions more Americans with the tools to help them live better longer. Pairing that with our new microdose GLP-1 program will help bend the curve on obesity rates in the United States.'
Noom Microdose GLP-1Rx Program includes: Microdose GLP-1 medication, if prescribed
Full access to the Noom GLP-1 Companion behavior and microhabits program
24/7 access to message doctors and care coordinators
Noom premium 1:1 health coaching
Prescription home delivery
Pricing: $119 to start and then $199 per month
Looking Ahead to Longevity
'GLP-1s with Noom's microhabit program represent a modern treatment for the ills of modernity,' said Cook. 'We help people sustain a healthy weight in a food environment engineered for dopamine-hits and excess consumption. By helping people limit compulsive eating and drinking, motivate movement, and reduce chronic inflammation, which we know GLP-1s can do, we promote a higher quality life.'
'The latest science demonstrates that we should be thinking about GLP-1 medication differently,' said Dr. Jeffrey Egler. 'GLP-1s are no longer only useful for weight loss and diabetes – they are critical for building metabolic resilience and reducing inflammation, making them a powerful component of whole-person, lasting health. For our patients, we see GLP-1s as the first step in an extraordinary journey to true vitality.'
The Microdose GLP-1Rx Program is available to Americans in 45 states at the following link: https://www.noom.com/med/glp1-microdose/
About Noom:
Noom is the leading whole-person health platform, combining personalized medication with psychology and habit science to help people take control of their metabolic health, weight, and longevity. Noom Health partners with top health plans and employers to offer a suite of solutions, including Noom Med, Noom Weight, Noom GLP-1 Companion, and Noom Diabetes Management and Diabetes Prevention Program to millions.
Founded on a mission to empower everyone everywhere to live better longer, Noom has received multiple National Institute of Health grants and was the first mobile app recognized by the CDC as a certified diabetes prevention program. With offices in New York City and Princeton, NJ, Noom has been named one of Inc.'s Best Places to Work, Quartz's Best Workplaces for Remote Workers, and Fortune's Best Workplaces in Technology.
Learn more at noom.com , subscribe to our blog , or follow us on Twitter and LinkedIn .
Contact:Brandyn Bissinger
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
Hims & Hers stock falls 10% on revenue miss
Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street's expectations for revenue. Here's how the company did based on average analysts' estimates compiled by LSEG: Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier. For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million. Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved. Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It's legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable. In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization. Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount. Hims & Hers will host its quarterly call with investors at 5 p.m. ET.
New York Post
6 hours ago
- New York Post
The future of post-weight loss skincare starts at IMAGE with these new products
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. In the world of modern aesthetics, few developments have sparked as much excitement — and concern— as the widespread use of GLP-1 medications for rapid weight loss. These groundbreaking therapies have offered millions a renewed sense of health and well-being. Yet, for all their benefits, they often leave one visible drawback: their impact on the skin. Rapid fat loss, particularly in the face, can lead to noticeable changes in skin appearance, including volume deflation, deepening wrinkles, dryness and a loss of density. Recognizing this, IMAGE Skincare has introduced a pioneering solution: the first clinically formulated skincare product designed specifically to combat the four visible effects of GLP-1-induced weight loss on the skin. Created by board-certified plastic surgeon Dr. Marc Ronert, isn't your run-of-the-mill anti-aging product. It represents a new category of targeted skincare. Advertisement IMAGE Skincare At the heart of its innovation is the GLP-1 4D Skin Rebound Complex, a proprietary blend of active ingredients meticulously chosen to address the four primary signs of facial skin aging resulting from rapid weight loss: deflation, deep wrinkles, dehydration and density loss. Dr. Ronert's approach reflects an intersection of medical science and aesthetic care, backed by years of experience treating patients who sought solutions for the facial aging effects that often follow significant weight reduction. What makes so unique is its focus on restoring what the skin loses during accelerated fat loss. Facial deflation, a hallmark of GLP-1 therapy use, can age the appearance dramatically by hollowing the cheeks and under-eye areas. The advanced volumizing technology in helps to counteract this process, encouraging a more lifted, youthful contour. After 12 weeks of consistent, twice-daily use, instrumental grading revealed a 20% increase in facial volume, underscoring the product's efficacy in restoring fullness to areas most impacted by fat depletion. But volume is only one part of the equation. The skin's structure also suffers under the strain of rapid weight loss, often resulting in sagging and loss of elasticity. The GLP-1 4D Skin Rebound Complex targets these issues with ingredients designed to improve skin's bounce and resilience. What's more, the results speak for themselves. Clinical testing showed a 23% increase in net elasticity and a 22% improvement in firmness after 12 weeks — measurable results that translate to tighter, more supple skin. These improvements not only address the visual signs of aging but also help the skin maintain its integrity as the face adapts to a new, leaner shape. Deep wrinkles, another byproduct of reduced fat cushioning in the face, are also visibly diminished with As facial support structures weaken and the skin thins, fine lines evolve into pronounced creases. is engineered to fill and smooth these lines by encouraging collagen synthesis and enhancing moisture retention. Users experienced a 20% reduction in wrinkles over a 12-week period, with noticeable improvement often beginning as early as four weeks. This means that while the transformation unfolds gradually, early signs of success are visible quickly, reinforcing the importance of consistent use. Dehydration, though often overlooked, is a critical aspect of post-weight-loss skin care. Skin that loses volume also loses its ability to retain moisture efficiently, leading to a dull, tired complexion. combats this with deeply hydrating components that strengthen the skin barrier and improve water retention, leaving the skin plumper, more radiant and visibly revitalized. This comprehensive approach is what sets apart; rather than treating symptoms in isolation, it addresses the interconnected causes behind the accelerated aging many experience after GLP-1 usage. Why You Can Trust IMAGE Skincare IMAGE Skincare What further elevates this innovation is the credibility and care behind its creation. IMAGE Skincare, founded in 2003 by aesthetician Janna Ronert, has always prioritized products that merge clean, botanical ingredients with clinical efficacy. The collaboration between Janna and Dr. Marc Ronert brings together the precision of surgical insight and the sensitivity of professional skincare. Their shared vision has positioned IMAGE Skincare as a leader in science-driven, physician-formulated solutions that are also cruelty-free and accessible to both professionals and consumers. continues this legacy with a product that feels luxurious while performing like a professional-grade treatment. The Final Verdict IMAGE Skincare For those navigating the often-unexpected changes to their appearance following GLP-1 weight loss, offers a reassuring and effective remedy. So, you can toss away your other serum and moisturizer for the time being, as this restorative treatment, designed with a deep understanding of the unique biological changes occurring beneath the surface of the skin, is one to impress. Every application helps the face rediscover its definition, its structure and its glow. And ultimately, represents a major advancement in personalized skincare. It anticipates a need that is growing rapidly as more individuals turn to metabolic treatments for weight management, and it delivers on that need with unmatched precision and efficacy. With visible improvements in volume, elasticity, firmness and wrinkle reduction (all within just a few months!) users can expect a smoother, fuller, more youthful complexion that reflects their internal transformation — with consistent use. Backed by clinical testing and guided by medical expertise, proves that you don't have to choose between your health goals and your appearance. You can have both: resilient skin that rebounds, just like you. This article was written by Victoria Giardina, New York Post Commerce Journalist & Content Strategist, who has spent countless hours researching, testing hundreds of products and comparing the latest makeup, skincare, hair and beauty items and trends to determine what's truly worth your hard-earned cash. She evaluates formulas, textures, ingredients and more, in addition to consulting medical and industry experts. Some of Victoria's latest conquests include testing the best vitamin C serums on the market, and a rinse-and-repeat review of the best shampoos of 2025. Victoria, who received a beauty industry essentials certification from the Fashion Institute of Technology, has been creating shopping guides for the New York Post since 2021 and previously held positions at Insider Reviews and CNN Underscored.
6 hours ago
Many US teens, young adults qualify for GLP-1 drugs but lack access
ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S. August 4, 2025
